3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
3
Completed
2
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Interventions
Cytarabine
35
Cyclophosphamide
30
fludarabine phosphate
24
fludarabine
24
Rituximab
20
Azacitidine
19
Methotrexate
17
venetoclax
16
Peripheral Blood Stem Cell Transplantation
14
Dasatinib
12
Bendamustine Hydrochloride
12
ibrutinib
11
Filgrastim
11
Busulfan
11
Whole-Body Irradiation
10
Granulocyte Colony-Stimulating Factor
10
Tacrolimus
9
Radiotherapy
9
Lenalidomide
8
Idarubicin
8
Decitabine
8
Vincristine
7
Etoposide
7
Dexamethasone
7
Daunorubicin
7
Cyclosporine
7
merphos
6
Prednisone
6
Melphalan
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
siremadlin
×
Other hematologic neoplasm
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn